Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares iBoxx $ Inv Grade Corporate Bond ETF (LQD) vs Health Care Select Sector SPDR Fund (XLV) Price & Performance

iShares iBoxx $ Inv Grade Corporate Bond ETFTrade
Health Care Select Sector SPDR FundTrade

Price performance (Past 24H)

Key statistics

iShares iBoxx $ Inv Grade Corporate Bond ETF vs Health Care Select Sector SPDR Fund — how do they compare? iShares iBoxx $ Inv Grade Corporate Bond ETF trades at $102.41 (market cap $28.50B), while Health Care Select Sector SPDR Fund trades at $170.81 (market cap $43.48B). The key difference: Health Care Select Sector SPDR Fund is the larger of the two by market cap, and Health Care Select Sector SPDR Fund is trading nearer its 52-week high, iShares iBoxx $ Inv Grade Corporate Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares iBoxx $ Inv Grade Corporate Bond ETF for 125 Days and Health Care Select Sector SPDR Fund for 100 Days on average.

LQDXLV
Market Cap
$28.50B$43.48B
Volume
37,320,11011,121,431
Sector
Fixed Income—
52-Week High
$112.91$175.68
52-Week Low
$101.83$141.95
Typical Hold Time
125 Days100 Days

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares iBoxx $ Inv Grade Corporate Bond ETF

LQD trades at $102.47 with a slight 0.34% daily gain amid a challenging bond market environment. The ETF shows bearish technical signals with moving averages indicating downward pressure, though oscillators remain neutral. Recent news highlights significant short interest growth of 53.1% in September 2026 and concerns about rising Treasury yields impacting investment-grade corporate bonds.

The outlook remains cautious as rising interest rates pressure bond ETFs, though LQD's 4.8% yield and high-quality portfolio provide some stability. Key risks include further bond market volatility and economic uncertainty, while institutional activity shows mixed sentiment with elevated short positions.

Health Care Select Sector SPDR Fund

XLV trades at $168.16, down 0.39% with a bearish technical signal from moving averages. The healthcare ETF maintains strong cost advantages with a 0.08% expense ratio compared to peers. Recent news highlights XLV's defensive positioning during market volatility and its historical outperformance during Fed rate hikes. Technical indicators show RSI levels in neutral territory while ADX signals selling pressure.

XLV offers diversified healthcare exposure with competitive expense ratios, positioning it well for defensive investing. Key risks include political uncertainty around healthcare policy and concentrated exposure to domestic S&P 500 stocks. The ETF's low-cost structure and sector diversification provide stability amid market volatility, though technical indicators suggest near-term caution.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

LQD

No sentiment data available yet.

XLV
44% Buy56% Sell
Avg holding period · 100 Days

About iShares iBoxx $ Inv Grade Corporate Bond ETF

The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in fixed income securities of the types included in the underlying index that the advisor believes will help the fund track the underlying index. The underlying index is designed to provide a broad representation of the US dollar-denominated liquid investment-grade corporate bond market.

Read more on LQD →

About Health Care Select Sector SPDR Fund

In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.

Read more on XLV →